Search

Your search keyword '"Eating disorders -- Drug therapy"' showing total 74 results
Start Over Descriptor "Eating disorders -- Drug therapy"
74 results on '"Eating disorders -- Drug therapy"'

1. The Medication Pipeline: Antidepressants and ADHD Rx

Author

Miller, John J.

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Schizophrenia -- Drug therapy, Attention-deficit hyperactivity disorder -- Drug therapy, Post-traumatic stress disorder -- Drug therapy, Neurophysiology, Health, Psychology and mental health
Abstract

In this second part of a 2 part series reviewing novel agents in the psychiatric pipeline, the focus is on treatments for unipolar major depressive disorder (MDD) and attention-deficit/hyperactivity disorder [...]

Published
2024

2. The Ozempic Aesthetic: Can Anti-Obesity Medications Cause More Harm Than Good?

Author

Climan, Anastasia

Subjects
Obesity -- Drug therapy, Eating disorders -- Drug therapy, Patient compliance, Medical societies, Type 2 diabetes -- Drug therapy, Evidence-based medicine, Weight loss -- Drug therapy, Health
Abstract

The American Medical Association officially recognized obesity as a disease in June 2013 after decades-long controversy.[sup.1] Although lifestyle interventions are promoted as a first-line obesity treatment, the resultant short-term weight [...]

Published
2023

3. Ozempic gains traction with celebrities

Author

Szczesniak, Alicia

Subjects
Celebrities, Eating disorders -- Drug therapy, Drug approval, Concerts -- Concert reviews, Weight loss -- Drug therapy, News, opinion and commentary, Sports and fitness, Ozempic (Medication)
Abstract

Byline: Alicia Szczesniak Content warning: eating disorders At the 2023 Academy Awards, Jimmy Kimmel took the stage as the host. During his opening monologue, he said, 'Everybody looks so great. [...]

Published
2024

4. Weight-loss drugs are challenging for people with eating disorders

Subjects
Eating disorders -- Drug therapy, Diabetes therapy, Drugs, Weight reducing preparations, Weight loss -- Drug therapy, Business, Computers and office automation industries, Telecommunications industry, Ozempic (Medication)
Abstract

Byline: Pamela Ramos; MD As a psychiatrist, my first day on an inpatient eating-disorders unit was shocking and confusing. Not because of the patients' actual weight, but because of how [...]

Published
2024

5. Weight-loss drugs are challenging for people with eating disorders

Author

Ramos, Pamela and Md

Subjects
Eating disorders -- Drug therapy, Diabetes therapy, Drugs, Weight reducing preparations, Weight loss -- Drug therapy, General interest, News, opinion and commentary, Ozempic (Medication)
Abstract

Byline: Pamela Ramos, MD As a psychiatrist, my first day on an inpatient eating disorders unit was shocking and confusing. Not because of the patientsÇÖ actual weight but because of [...]

Published
2024

6. Data on Antidepressants Reported by Researchers at University of Milan (Identification of a Novel Off-target of Paroxetine: Possible Role In Sexual Dysfunction Induced By This Ssri Antidepressant Drug)

Subjects
Eating disorders -- Drug therapy, Chronic pain -- Drug therapy, Depression, Mental -- Drug therapy, Paroxetine -- Dosage and administration -- Complications and side effects, Sexual disorders -- Risk factors -- Diagnosis -- Care and treatment, Health
Abstract

2022 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Antidepressants. According to [...]

Published
2022

7. Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Obesity in children -- Drug therapy, Prader-Willi syndrome -- Drug therapy, Drug approval, Clinical trials, General interest, News, opinion and commentary
Abstract

CHATHAM, N.J: Tonix Pharmaceuticals Holding Corp. has issued the following news release: Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, [...]

Published
2023

8. Recent Research from Harvard School of Dental Medicine Highlight Findings in Anxiety Disorders (Behavioral Health Within Primary Care Postgraduate Dental Curricula: a Mixed Methods Study)

Subjects
United States. Department of Health and Human Services -- Reports -- Analysis, Social service -- Methods -- Reports -- Analysis, Eating disorders -- Drug therapy, Mental health -- Analysis -- Reports -- Methods, Education -- Curricula, Behavioral health care -- Reports -- Analysis -- Methods, Anxiety -- Drug therapy, Health, Psychology and mental health
Abstract

2023 DEC 11 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Investigators publish new report on Mental Health Diseases and Conditions - Anxiety Disorders. [...]

Published
2023

9. Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 'POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Subjects
Eating disorders -- Drug therapy, Obesity in adolescence -- Drug therapy, Obesity in children -- Drug therapy, Pediatric cardiology -- Health aspects, Children -- Health aspects, Type 2 diabetes -- Drug therapy, Weight loss -- Drug therapy, Petroleum, energy and mining industries, Massachusetts General Hospital
Abstract

(GlobeNewswire) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 POWER study [...]

Published
2023

10. Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 'POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Subjects
Eating disorders -- Drug therapy, Obesity in children -- Drug therapy, Children -- Health aspects, Type 2 diabetes -- Drug therapy, Weight loss -- Drug therapy, Banking, finance and accounting industries, Business, Massachusetts General Hospital, Tosymra (Medication) -- Health aspects -- Product development
Abstract

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve as a Novel Neuroendocrine Weight-Loss Therapeutic for this Patient Population [...]

Published
2023

11. AAP vs. AED on obesity treatment: Is there a middle ground?

Author

Rettew, David C.

Subjects
Eating disorders -- Drug therapy, Obesity in adolescence -- Drug therapy, Obesity in children -- Drug therapy, Children -- Health aspects, Health, Health care industry
Abstract

The recent debate about how best to address the growing epidemic of obesity in children and adolescents has pitted different professional organizations against each other. While there is little controversy [...]

Published
2023

12. James Argent says doctors sent him to eating disorder unit during rehab stint in 2014; James Argent went to rehab in 2014 to treat his drug addiction and found out about his eating disorder during that stint

Subjects
Eating disorders -- Drug therapy, Addiction -- Drug therapy, General interest, News, opinion and commentary
Abstract

Byline: By, Zara Woodcock James Argent said doctors had sent him to an eating disorder unit during his first rehab stint in 2014. The former The Only Way Is Essex [...]

Published
2022

13. Novel research finds combined ED, PTSD treatment effective

Subjects
Eating disorders -- Drug therapy, Post-traumatic stress disorder -- Drug therapy, Evidence-based medicine, Law, Psychology and mental health
Abstract

Based upon principles of cognitive processing therapy (CPT), one of the leading disorder providers in the country embarked on what officials are calling groundbreaking research to show the effectiveness of [...]

Published
2023

15. Sertraline in underweight binge eating/purging-type eating disorders: five case reports

Author

Frank, Guido K., Kaye, Walter H., and Marcus, Marsha D.

Subjects
Eating disorders -- Drug therapy, Serotonin -- Research, Sertraline -- Health aspects, Food/cooking/nutrition, Psychology and mental health
Abstract

Five case studies are reported of the response of underweight binge eating/purging-type eating disordered women to the selective serotonin reuptake inhibitor sertraline.

Published
2001

16. Medically-supervised pediatric obesity treatment associated with improved psychosocial health, but access to care is limited

Subjects
Novo Nordisk A/S, Eating disorders -- Drug therapy, Pediatrics -- Psychological aspects, Obesity in children -- Drug therapy, Mental health -- Psychological aspects, Children -- Health aspects, Evidence-based medicine -- Psychological aspects, Pharmaceutical industry -- Psychological aspects, Health, Psychology and mental health
Abstract

2021 SEP 6 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- SILVER SPRING, Md.-Medically-supervised pediatric obesity treatment is associated with improved psychosocial health and [...]

Published
2021

17. What are eating disorder patients taking? Clinicians need to recognize over-the-counter drug use in clients with eating disorders

Author

Wandler, Kevin R. and Lee, Yong B.

Subjects
Medical research, Medicine, Experimental, Nonprescription drugs, Eating disorders -- Drug therapy, Medicine, Botanic, Clinical psychiatry, Medicine, Herbal, Health, Health care industry, Psychology and mental health, Drug therapy
Abstract

Americans purchase over-the-counter medications to treat an amazing array of problems: colds, diarrhea, headaches, even baldness. Americans also purchase a range of herbal preparations that purportedly slow aging, increase attention, [...]

Published
2007

18. Pharmacotherapy of bulimia nervosa and binge eating disorder

Author

Walsh, B. Timothy and Devlin, Michael J.

Subjects
Bulimia -- Drug therapy, Eating disorders -- Drug therapy, Antidepressants -- Health aspects, Drug therapy -- Research, Health, Sociology and social work
Abstract

Studies have shown that antidepressant medication is useful in treating bulimia nervosa. There is also a link between the use of antidepressant medication and a decrease in binge frequency in obese individuals with binge eating disorder. However, it does not lead to weight loss. Further research is suggested on predictive factors, long-term response and pharmacotherapy. One promising area that needs research is the use of appetite suppressant medications in the treatment of eating disorders.

Published
1995

19. The relationship between severe mental illness and diabetes

Subjects
Type 2 diabetes -- Research, Type 2 diabetes -- Drug therapy, Type 2 diabetes -- Risk factors, Type 2 diabetes -- Surveys, Type 2 diabetes -- Physiological aspects, Type 2 diabetes -- Analysis, Type 2 diabetes -- Reports, Bipolar disorder -- Research, Bipolar disorder -- Drug therapy, Bipolar disorder -- Risk factors, Bipolar disorder -- Surveys, Bipolar disorder -- Physiological aspects, Bipolar disorder -- Analysis, Bipolar disorder -- Reports, Blood sugar monitoring -- Surveys, Blood sugar monitoring -- Physiological aspects, Blood sugar monitoring -- Analysis, Blood sugar monitoring -- Reports, Antipsychotic drugs -- Research, Antipsychotic drugs -- Surveys, Antipsychotic drugs -- Physiological aspects, Antipsychotic drugs -- Analysis, Antipsychotic drugs -- Reports, Glucose tolerance tests -- Surveys, Glucose tolerance tests -- Physiological aspects, Glucose tolerance tests -- Analysis, Glucose tolerance tests -- Reports, Prediabetic state -- Research, Prediabetic state -- Drug therapy, Prediabetic state -- Risk factors, Prediabetic state -- Surveys, Prediabetic state -- Physiological aspects, Prediabetic state -- Analysis, Prediabetic state -- Reports, Blood sugar -- Surveys, Blood sugar -- Physiological aspects, Blood sugar -- Analysis, Blood sugar -- Reports, Medical research -- Surveys, Medical research -- Physiological aspects, Medical research -- Analysis, Medical research -- Reports, Medicine, Experimental -- Surveys, Medicine, Experimental -- Physiological aspects, Medicine, Experimental -- Analysis, Medicine, Experimental -- Reports, Carbohydrate metabolism -- Surveys, Carbohydrate metabolism -- Physiological aspects, Carbohydrate metabolism -- Analysis, Carbohydrate metabolism -- Reports, Obesity -- Research, Obesity -- Drug therapy, Obesity -- Risk factors, Obesity -- Surveys, Obesity -- Physiological aspects, Obesity -- Analysis, Obesity -- Reports, Hyperglycemia -- Research, Hyperglycemia -- Drug therapy, Hyperglycemia -- Risk factors, Hyperglycemia -- Surveys, Hyperglycemia -- Physiological aspects, Hyperglycemia -- Analysis, Hyperglycemia -- Reports, Somatotropin -- Research, Somatotropin -- Surveys, Somatotropin -- Physiological aspects, Somatotropin -- Analysis, Somatotropin -- Reports, Glucose metabolism -- Surveys, Glucose metabolism -- Physiological aspects, Glucose metabolism -- Analysis, Glucose metabolism -- Reports, Dementia -- Research, Dementia -- Drug therapy, Dementia -- Risk factors, Dementia -- Surveys, Dementia -- Physiological aspects, Dementia -- Analysis, Dementia -- Reports, Schizophrenia -- Research, Schizophrenia -- Drug therapy, Schizophrenia -- Risk factors, Schizophrenia -- Surveys, Schizophrenia -- Physiological aspects, Schizophrenia -- Analysis, Schizophrenia -- Reports, Chronic diseases -- Research, Chronic diseases -- Drug therapy, Chronic diseases -- Risk factors, Chronic diseases -- Surveys, Chronic diseases -- Physiological aspects, Chronic diseases -- Analysis, Chronic diseases -- Reports, Insulin resistance -- Research, Insulin resistance -- Surveys, Insulin resistance -- Physiological aspects, Insulin resistance -- Analysis, Insulin resistance -- Reports, Leptin -- Surveys, Leptin -- Physiological aspects, Leptin -- Analysis, Leptin -- Reports, Diabetes therapy -- Surveys, Diabetes therapy -- Physiological aspects, Diabetes therapy -- Analysis, Diabetes therapy -- Reports, Eating disorders -- Research, Eating disorders -- Drug therapy, Eating disorders -- Risk factors, Eating disorders -- Surveys, Eating disorders -- Physiological aspects, Eating disorders -- Analysis, Eating disorders -- Reports, Peptide hormones -- Surveys, Peptide hormones -- Physiological aspects, Peptide hormones -- Analysis, Peptide hormones -- Reports, Corticosteroids -- Research, Corticosteroids -- Surveys, Corticosteroids -- Physiological aspects, Corticosteroids -- Analysis, Corticosteroids -- Reports, Health
Published
2003

20. After Prozac: will you become your old self again? Do you want to?

Author

Bonavoglia, Angela

Subjects
Antidepressants -- Personal narratives, Eating disorders -- Drug therapy, Women's issues/gender studies, Prozac (Medication) -- Personal narratives
Abstract

A woman with a binge eating disorder spent nearly three years on Prozac. She kicked it when her ambition, energy, and clarity declined, but fought nightmares and her eating disorder again.

Published
1997

21. Saniona's partner Medix submits new drug application in Mexico for tesofensine in obesity

Subjects
Obesity -- Drug therapy, Eating disorders -- Drug therapy, Drug approval, Biotechnology, Biotechnology industries, General interest, News, opinion and commentary
Abstract

Ballerup: Saniona AB has issued the following press release: Saniona (OMX: SANION), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix has [...]

Published
2019

22. Sanionas partner Medix submits new drug application in Mexico for tesofensine in obesity

Subjects
Obesity -- Drug therapy, Eating disorders -- Drug therapy, Type 2 diabetes -- Drug therapy, Drug approval, Biotechnology, Anorexia nervosa, Biotechnology industries, Business, international, Law
Abstract

(GlobeNewswire) - PRESS RELEASE December 23, 2019 Saniona (OMX: SANION), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix has submitted a [...]

Published
2019

23. Saniona's partner Medix submits new drug application in Mexico for tesofensine in obesity

Subjects
Obesity -- Drug therapy, Eating disorders -- Drug therapy, Type 2 diabetes -- Drug therapy, Drug approval, Biotechnology, Anorexia nervosa, Biotechnology industries, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- PRESS RELEASE December 23, 2019 Saniona (OMX: SANION), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix [...]

Published
2019

24. Insight Behavioral Health Centers Brings Expertise in the Treatment of Mood, Anxiety and Trauma-Related Conditions to Colorado

Subjects
Eating disorders -- Drug therapy, Evidence-based medicine, Behavioral medicine, Mental health services, Trauma (Psychology) -- Drug therapy, Youth, Business, international, Law
Abstract

(GlobeNewswire) - In response to the growing need for comprehensive, specialized mental health services in Colorado, Insight Behavioral Health Centers (Insight), a leading treatment provider for mood, anxiety and trauma-related [...]

Published
2019

25. Insight Behavioral Health Centers Brings Expertise in the Treatment of Mood, Anxiety and Trauma-Related Conditions to Colorado

Subjects
Eating disorders -- Drug therapy, Evidence-based medicine, Behavioral medicine, Mental health services, Trauma (Psychology) -- Drug therapy, Youth, Banking, finance and accounting industries, Business
Abstract

Denver, CO, Dec 02, 2019 (GLOBE NEWSWIRE via COMTEX) -- In response to the growing need for comprehensive, specialized mental health services in Colorado, Insight Behavioral Health Centers (Insight), a [...]

Published
2019

26. Findings on Eating Disorders Detailed by Investigators at National University of Singapore (The Efficacy of Virtual Reality In the Treatment of Binge-purging Eating Disorders: a Meta-analysis)

Subjects
Virtual reality -- Reports, Eating disorders -- Drug therapy, Medical research -- Reports, Cognitive-behavioral therapy -- Reports, Virtual reality technology, Health, Psychology and mental health, National University of Singapore -- Reports
Abstract

2020 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Investigators publish new report on Eating Disorders. According to news reporting originating in [...]

Published
2020

27. Research from Institute for Cancer Research and Treatment (IRCCS) Reveals New Findings on Anorexia (Multimodal neuroimaging in anorexia nervosa)

Subjects
Cancer treatment -- Reports, Eating disorders -- Drug therapy, Cancer -- Drug therapy, Cancer research -- Reports, Mental health -- Reports, Health, Psychology and mental health
Abstract

2020 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Research findings on Eating Disorders - Anorexia are discussed in a new report. [...]

Published
2020

28. PIPELINE

Subjects
Eating disorders -- Drug therapy, Monoclonal antibodies, Antiarrhythmia agents, Bimatoprost, Type 1 diabetes -- Drug therapy, RNA interference, Antibodies, Cardiovascular diseases, Hypercholesterolemia, Minocycline, Low density lipoproteins, Orphan drugs, Health
Abstract

* Cardiovascular Disease ARO-ANG3 (Arrowhead) an RNAi therapy formulated as a subcutaneous injection for the treatment of homozygous familial hypercholesterolemia-Orphan Drug Designation granted Vernakalant (Brinavess; Correvio) an intravenous antiarrhythmic agent [...]

Published
2019

29. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study

Author

McCann, Una D. and Agras, W. Stewart

Subjects
Bulimia -- Drug therapy, Desipramine -- Health aspects, Antidepressants -- Health aspects, Eating disorders -- Drug therapy, Health, Psychology and mental health
Abstract

Bulimia nervosa is characterized by regular binge eating which is usually followed by purging, by either self-induced vomiting or use of laxatives. However, there is a subgroup of patients with this disorder who binge, but do not purge. Antidepressant medications such as desipramine have been found to be helpful in those with purging bulimia. This study examined the efficacy of this drug in 23 women with non-purging bulimia. All of the subjects had a history of binging behavior for at least one year, which occurred at least twice a week; all of the women considered themselves overweight and most of them were. For 12 weeks, 10 subjects were given desipramine and 13 subjects were given a placebo. The women had been screened prior to the trial for other mental disorders or medical problems. At follow-up, the number of weekly binge eating episodes was reduced by 63 percent in the women who received desipramine. Binge eating in the group receiving the placebo increased by 16 percent over the same time period. In addition, 60 percent of the drug-treated group, but only 15 percent of the placebo group, were able to refrain from binging completely by the end of the trial. Not only did the women receiving desipramine report fewer binging episodes, they also reported less hunger during the treatment period. Although these results are preliminary, they suggest that non-purging bulimics may benefit from desipramine treatment. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

30. Drop-dead beautiful Part 2: destructive eating disorders can be treated successfully using the right combination of therapy and love

Author

Schwirzer, Jennifer J.

Subjects
Eating disorders -- Care and treatment, Eating disorders -- Drug therapy, Behavior therapy -- Usage, Family psychotherapy -- Usage
Abstract

Today anorexia (prolonged limiting of food intake) and bulimia binge eating followed by purging) have taken center stage in the dieting fixation saga. More and more people--mostly women, mostly young--are [...]

Published
2005

31. A prevalence study and Description of alli[R] use by patients with eating disorders

Author

Steffen, Kristine J., Mitchell, James E., Grange, Daniel le, Crow, Scott J., Attia, Evelyn, Bulik, Cynthia M., Dellava, Jocilyn E., Bermudez, Ovidio, Erickson, Ann L., Crosby, Ross D., and Bansal-Dev, Vidhu P.

Subjects
Appetite depressants -- Health aspects, Eating disorders -- Diagnosis, Eating disorders -- Drug therapy, Food/cooking/nutrition, Psychology and mental health, Alli (Medication) -- Health aspects
Published
2010

32. London Integrated Diabetes And Mental Health Pathway For The Treatment Of Type 1 Diabetes With Disordered Eating And Insulin Reduction

Subjects
Eating disorders -- Drug therapy, Diabetes therapy, Mental health, Type 1 diabetes -- Drug therapy, Insulin, Business, international
Abstract

Contract: london integrated diabetes and mental health pathway for the treatment of type 1 diabetes with disordered eating and insulin reduction London integrated diabetes and mental health pathway for the [...]

Published
2018

33. Eating Recovery Center Expands Mood, Anxiety and Trauma Treatment

Subjects
Depression (Mood disorder) -- Drug therapy, Eating disorders -- Drug therapy, Evidence-based medicine, Behavioral medicine, Mental health, Anxiety -- Drug therapy, Trauma (Psychology) -- Drug therapy, Business, general
Abstract

DENVER (PRWEB) July 17, 2018 Eating Recovery Center (ERC) announces today the expansion of its mood, anxiety, and trauma treatment programming to network centers in Houston and San Antonio, TX, [...]

Published
2018

34. Saniona plans Phase 2a study for treatment of Hypothalamic Obesity

Subjects
Clinical trials, Brain, Eating disorders -- Drug therapy, Prader-Willi syndrome -- Drug therapy, Company business planning, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- PRESS RELEASE June 11, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it plans to initiate a clinical Phase 2a study [...]

Published
2018

35. Eating Recovery Center Opens Mood and Anxiety Intensive Treatment Program in Seattle; Expands Eating Disorder Treatment Program

Subjects
Eating disorders -- Drug therapy, Evidence-based medicine, Substance abuse treatment, Behavioral medicine, Anxiety -- Drug therapy, Business, general
Abstract

SEATTLE (PRWEB) March 14, 2018 Eating Recovery Center announces today the opening of its mood and anxiety program in Seattle, Washington. Insight Behavioral Health Center, a provider of comprehensive treatment [...]

Published
2018

37. Zolpidem induced nocturnal sleep-related eating disorder (NSRED) in a male patient

Author

Dang, Amit, Garg, Gaurav, and Rataboli, Padmanabh V.

Subjects
Zolpidem -- Usage, Zolpidem -- Health aspects, Eating disorders -- Physiological aspects, Eating disorders -- Drug therapy, Eating disorders -- Case studies, Middle aged persons -- Health aspects, Food/cooking/nutrition, Psychology and mental health
Published
2009

38. US FDA accepts Sunovion Pharmaceuticals' New Drug Application for Dasotraline

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Medical research, Clinical trials, Phenols (Class of compounds), Binge eating disorder, Chemistry
Abstract

M2 PHARMA-August 1, 2019-US FDA accepts Sunovion Pharmaceuticals' New Drug Application for Dasotraline (C)2019 M2 COMMUNICATIONS The US Food and Drug Administration (FDA) has accepted United States-based Sunovion Pharmaceuticals' New [...]

Published
2019

39. US FDA accepts Sunovion Pharmaceuticals' New Drug Application for Dasotraline

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Medical research, Clinical trials, Phenols (Class of compounds), Binge eating disorder, Business
Abstract

M2 EQUITYBITES-August 1, 2019-US FDA accepts Sunovion Pharmaceuticals' New Drug Application for Dasotraline (C)2019 M2 COMMUNICATIONS http://www.m2.com The US Food and Drug Administration (FDA) has accepted United States-based Sunovion Pharmaceuticals' [...]

Published
2019

40. Researchers at Stanford University School of Medicine Target Obesity (Healthy Teens @ School: Evaluating and disseminating transdiagnostic preventive interventions for eating disorders and obesity for adolescents in school settings)

Subjects
Adolescent obesity -- Drug therapy, Youth, Eating disorders -- Drug therapy, Mental health, Editors, Health, Psychology and mental health
Abstract

2019 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Fresh data on Nutritional and Metabolic Diseases and Conditions - Obesity are presented [...]

Published
2019

41. The use of herbal remedies by adolescents with eating disorders

Author

Trigazis, Leo, Tennankore, Dhenuka, Vohra, Sunita, and Katzman, Debra K.

Subjects
Teenage girls -- Health aspects, Eating disorders -- Drug therapy, Eating disorders -- Research, Medicine, Botanic -- Dosage and administration, Medicine, Herbal -- Dosage and administration, Food/cooking/nutrition, Psychology and mental health
Abstract

A study is made regarding the usage of herbal remedies, their frequency and type by adolescent females with eating disorders. Of the 46 subjects, 37% used herbal remedies to decrease their appetite and to induce vomiting and finally was found that adolescents used herbal remedies for weight control and non-weight control without informing their physicians.

Published
2004

42. The eating disorders medicine cabinet revisited: a clinician's guide to appetite suppressants and diuretics

Author

Roerig, James L., Mitchell, James E., de Zwann, Martina, Wonderlich, Stephen A., Kamran, Shehzad, Engbloom, Sara, Burgard, Melissa, and Lancaster, Kathryn

Subjects
Diuretics -- Research, Eating disorders -- Drug therapy, Bulimia -- Drug therapy, Appetite depressants -- Research, Food/cooking/nutrition, Psychology and mental health
Abstract

A high proportion of patients seeking treatment for bulimia tended to purchase alternative medicines. Most common were diet pills and diuretics, many with potentially significant toxicities.

Published
2003

43. Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Attention deficit hyperactivity disorder -- Drug therapy, Business, Business, international
Abstract

MARLBOROUGH, Mass. -- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline, a novel [...]

Published
2017

44. Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD

Subjects
United States. Food and Drug Administration, Eating disorders -- Drug therapy, Attention deficit hyperactivity disorder -- Drug therapy, Medical research, Business, Business, international, American Psychiatric Association
Abstract

- Pharmacokinetic properties and clinical studies of dasotraline, a new chemical entity, support potential for continuous therapeutic effect over 24-hour dosing interval with once-daily dosing - MARLBOROUGH, Mass. -- Sunovion [...]

Published
2017

45. Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity

Subjects
Clinical trials, Brain, Eating disorders -- Drug therapy, Prader-Willi syndrome -- Drug therapy, Company business planning, Chemistry
Abstract

M2 PHARMA-June 12, 2018-Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity (C)2018 M2 COMMUNICATIONS Biotechnology company Saniona AB (STO:SANION) announced on Monday that [...]

Published
2018

46. Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity

Subjects
Clinical trials, Brain, Eating disorders -- Drug therapy, Prader-Willi syndrome -- Drug therapy, Company business planning, Business
Abstract

M2 EQUITYBITES-June 12, 2018-Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity (C)2018 M2 COMMUNICATIONS http://www.m2.com Biotechnology company Saniona AB (STO:SANION) announced on Monday [...]

Published
2018

47. Saniona plans Phase 2a study for hypothalamic obesity treatment

Subjects
Brain, Obesity -- Drug therapy, Eating disorders -- Drug therapy, Tumor removal, Company business planning, Chemistry
Abstract

M2 PHARMA-June 11, 2018-Saniona plans Phase 2a study for hypothalamic obesity treatment (C)2018 M2 COMMUNICATIONS Saniona AB (STO: SANION) announced on Monday plans to begin a clinical Phase 2a Tesomet [...]

Published
2018

48. Saniona plans Phase 2a study for hypothalamic obesity treatment

Subjects
Brain, Obesity -- Drug therapy, Eating disorders -- Drug therapy, Tumor removal, Company business planning, Business
Abstract

M2 EQUITYBITES-June 11, 2018-Saniona plans Phase 2a study for hypothalamic obesity treatment (C)2018 M2 COMMUNICATIONS http://www.m2.com Saniona AB (STO: SANION) announced on Monday plans to begin a clinical Phase 2a [...]

Published
2018

49. The Ultimate Diet Pill?

Author

Andrews, Michelle

Subjects
Weight loss -- Methods, Appetite depressants -- Licensing, certification and accreditation, Appetite depressants -- Physiological aspects, Appetite depressants -- Dosage and administration, Eating disorders -- Drug therapy
Published
2006

50. Giuliana Rancic hits back at weight critics: 'I look in the mirror and it's hard for me'; The E! News presenter slams eating disorder rumours and reveals that her cancer treatment is to blame

Subjects
Cancer treatment, Eating disorders -- Drug therapy, General interest, News, opinion and commentary
Abstract

Byline: Claire Rutter Giuliana Rancic has kept quiet as people continue to slam her tiny frame, even when she's been accused of having an eating disorder -- until now. The [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results